MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients

Stopped Due to the rapid shifting of liver cancer disease landscape and the company's adjustment of development strategy.

Conditions

• Advanced Hepatocellular Carcinoma (HCC)

Interventions

• DRUG: MGD013 monotherapy
• DRUG: MGD013 in combination with Brivanib Alaninate

Sponsor

Zai Lab (Shanghai) Co., Ltd.